ESMO Presentation, page-22

what is this comedy night.... Are you seriously trying to blame me in some small way for today market action.

Further, you are missing the key point here. carboplatin worked in producing a PFS of 20 weeks by itself . The palecob given with this weekly auc2 produced a PFS of 20 weeks. See below quote bearing that very point that SD was achieved....

"However, while there was no RECIST response, or CA125 response by GCIG criteria, the PFS in both arms was typical of chemotherapy in PROC. While it is not clear whether every patient was progressing at the time of entry, one could conclude that carboplatin led to SD in both arms and that this had some clinical utility. " https://academic.oup.com/annonc/article/25/1/160/166169

We are kept being told that these patients are no longer responding to carboplatin, but here is a study showing PFS of 20 weeks with just carboplatin by itself and describe as typical......and in low weekly dosage that are deemed inactive

"In addition, single-agent weekly AUC2-carboplatin appeared to be inactive by response criteria in a homogenously defined population of PROC. This has implications for the design of future studies." https://www.ncbi.nlm.nih.gov/CBBres...splay=1&snp_display=1&Mutation_display=1&tax=